Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6B33

Structure of RORgt in complex with a novel inverse agonist 3

6B33 の概要
エントリーDOI10.2210/pdb6b33/pdb
分子名称Nuclear receptor ROR-gamma, (2R)-N~2~-(3-chloro-4-cyanophenyl)-N~4~-[3-(cyclopropylmethyl)-2,4-dioxo-1-(propan-2-yl)-1,2,3,4-tetrahydroquinazolin-6-yl]morpholine-2,4-dicarboxamide (3 entities in total)
機能のキーワードcomplex, inverse agonist, nuclear hormone receptor, signaling protein-antagonist complex, signaling protein/antagonist
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計51902.75
構造登録者
Skene, R.J.,Hoffman, I.,Snell, G. (登録日: 2017-09-20, 公開日: 2018-11-21, 最終更新日: 2024-03-13)
主引用文献Sato, A.,Fukase, Y.,Kono, M.,Ochida, A.,Oda, T.,Sasaki, Y.,Ishii, N.,Tomata, Y.,Fukumoto, S.,Imai, Y.N.,Uga, K.,Shibata, A.,Yamasaki, M.,Nakagawa, H.,Shirasaki, M.,Skene, R.,Hoffman, I.,Sang, B.C.,Snell, G.,Shirai, J.,Yamamoto, S.
Design and Synthesis of Conformationally Constrained ROR gamma t Inverse Agonists.
Chemmedchem, 2019
Cited by
PubMed Abstract: Retinoic-acid-related orphan receptor γt (RORγt) inverse agonists could be used for the treatment of autoimmune diseases. Previously, we reported a novel quinazolinedione 1 a with a flexible linear linker as a novel RORγt inverse agonist. A U-shaped conformation in the complex structure of 1 a with RORγt protein was confirmed. Further improvement of the pharmacokinetic (PK) profiles was required because of the low drug exposure in mice upon oral administration (mouse AUC of 1 a: 27 ng ⋅ h ⋅ mL at 1 mg ⋅ kg , p.o.). To improve the PK profiles, conformationally constrained U-shaped scaffolds were investigated. As a result, morpholine analogues with improved PK profiles and high potency were successfully identified. The substituent at the N1 position of the quinazoline moiety was also modified, leading to an enhancement of reporter activity. Consequently, compound 43 (N -(3-chloro-4-cyanophenyl)-N -(3-(cyclopropylmethyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)morpholine-2,4-dicarboxamide) exhibited improved drug exposure (mouse AUC: 1289 ng ⋅ h ⋅ mL at 1 mg ⋅ kg , p.o.). In addition, suppression of IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model was observed for 43. The conformation of 43 with RORγt protein was also confirmed as U-shape by X-ray co-crystal structure analysis. The key interaction that boosts potency is also discussed.
PubMed: 31659845
DOI: 10.1002/cmdc.201900416
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.48 Å)
構造検証レポート
Validation report summary of 6b33
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon